In the WHO-5 classification of hematolymphoid disorders (2022), TP53-mutated MDS (0–19% blast count) requires bi-allelic inactivation—defined as a TP53 mutation accompanied by either a second mutation or a copy-number loss/cnLOH) [5,8]. Here, TP53 is linked to myelodysplastic syndrome.